Dov Bergwerk, Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd., filed a Form 4 on November 12, 2026, reporting the acquisition of 9,433 restricted share units on November 10, 2026.
Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd., filed a Form 4 on November 12, 2026, reporting the exercise of stock options and the same-day sale of 44,710 ordinary shares.
Richard D. Francis, President and CEO of Teva Pharmaceutical Industries Ltd., filed a Form 4 on November 12, 2026, reporting the sale of 250,000 ordinary shares on November 10, 2026, pursuant to a Rule 10b5-1 trading plan.
Director David J. Brailer filed a Form 3 initial statement of beneficial ownership with the SEC on November 12, 2026, reporting his status as a newly affiliated director of Teva Pharmaceutical Industries Ltd. as of November 3, 2026.
Director John W. Kozarich of Ligand Pharmaceuticals Inc filed a Form 144 notice on November 12, 2026, proposing the sale of 500 shares of Ligand common stock through UBS Financial Services, Inc., with an approximate sale date of November 12, 2026.
Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd, filed a Form 144 notice on November 12, 2026, proposing the sale of 44,710 ordinary shares acquired through a stock option exercise and sale on the same date.
Director Anne Prener of Keros Therapeutics, Inc. filed a Form 144 notice on November 12, 2026, disclosing a proposed sale of 574 shares of common stock acquired through RSU vesting, with an aggregate market value of $5,619.00.
Innovex International, Inc. officer Reed Kendal filed a Form 144 notice of proposed sale of 20,868 shares of common stock on November 12, 2026, pursuant to Rule 144 under the Securities Act of 1933.
Alphabet Inc. director John L. Hennessy filed a Form 144 notice of proposed sale of 300 Class A Common shares on November 12, 2026, with UBS Financial Services, Inc. acting as broker on the Nasdaq exchange.
Christen Kozlik, an officer of Acel Entertainment, Inc., filed a Form 144 notice of proposed sale on November 12, 2026, disclosing plans to sell 3,600 shares of the company's common stock on the New York Stock Exchange.